At present, the immune checkpoint inhibitors (ICIs) including programmed cell death protein 1 (PD-1) or its ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been approved for certain types of cancer (Miller et al., 2019). The gene discussed is PDCD1; the disease is cancer.